Neural modulation for hypertension and heart failure

International Journal of Cardiology

Volumn 214, Issue , 2016, Pages 320-330

  Smith, S ^a   Rossignol, P ^b   Willis, S ^a   Zannad, F ^b   Mentz, R ^c   Pocock, S ^d   Bisognano, J ^e   Nadim, Y ^f   Geller, N ^g   Ruble, S ^h   Linde, C ⁱ  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^f CVRX INC   (United States)

^g NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^h Boston Scientific CRV   (United States)

ⁱ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Baroreceptor; Heart failure; Hypertension; Neural modulation; Renal denervation

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; IVABRADINE; PLACEBO; SACUBITRIL PLUS VALSARTAN; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; ANTIHYPERTENSIVE AGENT;

ARTICLE; AUTONOMIC NERVOUS SYSTEM; BARORECEPTOR ACTIVATION THERAPY; CARDIAC RESYNCHRONIZATION THERAPY; CAROTID SINUS PRESSORECEPTOR REFLEX; CATHETER ABLATION; COUGHING; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG WITHDRAWAL; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; IMPLANTABLE CAROTID SINUS STIMULATOR; IMPLANTABLE PULSE GENERATOR; IMPLANTED VAGUS NERVE STIMULATOR; KIDNEY ARTERY; KIDNEY DENERVATION; MEDICAL DEVICE COMPLICATION; NEUROMODULATION; NEW YORK HEART ASSOCIATION CLASS; NONHUMAN; NONSURGICAL INVASIVE THERAPY; PATIENT SELECTION; PRIORITY JOURNAL; RESISTANT HYPERTENSION; SHAM PROCEDURE; SODIUM RETENTION; SYMPATHECTOMY; SYMPATHETIC TONE; VAGUS NERVE STIMULATION; CLINICAL TRIAL (TOPIC); IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MULTIMODALITY CANCER THERAPY; PROCEDURES; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DEFIBRILLATORS, IMPLANTABLE; HEART FAILURE; HUMANS; HYPERTENSION; TREATMENT OUTCOME; VAGUS NERVE STIMULATION;

EID: 84963542013     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.03.078     Document Type: Review

References (115)

1. D. Mozaffarian, E.J. Benjamin, A.S. Go, and et al. Heart disease and stroke statistics - 2015 update: a report from the american heart association Circulation 131 4 2015 e29 e322
2. J. Fang, Q. Yang, Y. Hong, and F. Loustalot Status of cardiovascular health among adult Americans in the 50 States and the District of Columbia J Am Heart Assoc 2012 2009 1:e005371
3. U. Sartipy, U. Dahlstrom, M. Edner, and L.H. Lund Predicting survival in heart failure: validation of the MAGGIC heart failure risk score in 51,043 patients from the swedish heart failure registry Eur J Heart Fail 16 2 2014 173 179
4. F. Zannad, J.J. McMurray, H. Krum, and et al. Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 364 1 2011 11 21
5. K.T. Weber Aldosterone in congestive heart failure N Engl J Med 345 23 2001 1689 1697
6. J.J. McMurray, M. Packer, A.S. Desai, and et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure N Engl J Med 371 11 2014 993 1004
7. B. Williams, T.M. MacDonald, S. Morant, and et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial Lancet 2015
8. O.Y. Hai, R.J. Mentz, F. Zannad, and et al. Cardiac resynchronization therapy in heart failure patients with less severe left ventricular dysfunction Eur J Heart Fail 17 2 2015 135 143
9. P.A. James, S. Oparil, B.L. Carter, and et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint national committee (JNC 8) JAMA 311 5 2014 507 520
10. G. Mancia, R. Fagard, K. Narkiewicz, and et al. 2013 ESH/ESC practice guidelines for the management of arterial hypertension Blood Press 23 1 2014 3 16
11. P.A. Sarafidis, P. Georgianos, and G.L. Bakris Resistant hypertension - its identification and epidemiology Nat Rev Nephrol 9 1 2013 51 58
12. A.K. Gupta, E.G. Nasothimiou, C.L. Chang, and et al. Baseline predictors of resistant hypertension in the anglo-scandinavian cardiac outcome trial (ASCOT): a risk score to identify those at high-risk J Hypertens 29 10 2011 2004 2013
13. J.A. Shaw, and J.L. Warren Resistant hypertension and renal denervation where to now? Cardiovasc Ther 33 1 2015 9 14
14. G.F. DiBona Sympathetic nervous system and the kidney in hypertension Curr Opin Nephrol Hypertens 11 2 2002 197 200
15. G.F. DiBona, and U.C. Kopp Neural control of renal function Physiol Rev 77 1 1997 75 197
16. E. Pimenta, K.K. Gaddam, and S. Oparil Mechanisms and treatment of resistant hypertension J Clin Hypertens (Greenwich) 10 3 2008 239 244
17. E. Pimenta, K.K. Gaddam, M.N. Pratt-Ubunama, and et al. Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension Hypertension 51 2 2008 339 344
18. M. Esler Renal denervation for treatment of drug-resistant hypertension Trends Cardiovasc Med 25 2 2015 107 115
19. J.P. Singh, J. Kandala, and A.J. Camm Non-pharmacological modulation of the autonomic tone to treat heart failure Eur Heart J 35 2 2014 77 85
20. M.A. Pfeffer, K. Swedberg, C.B. Granger, and et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme Lancet 362 9386 2003 759 766
21. Effects of enalapril on mortality in severe congestive heart failure. results of the cooperative north scandinavian enalapril survival study (CONSENSUS). The CONSENSUS trial study group N Engl J Med 316 23 1987 1429 1435
22. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD investigators N Engl J Med 327 10 1992 685 691
23. I.S. Anand, P. Carson, E. Galle, and et al. Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure: Results from the comparison of medical therapy, pacing and defibrillation in heart failure (COMPANION) trial Circulation 119 7 2009 969 977
24. J.G. Cleland, J.C. Daubert, E. Erdmann, and et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure N Engl J Med 352 15 2005 1539 1549
25. M. St John Sutton, S. Ghio, T. Plappert, and et al. Cardiac resynchronization induces major structural and functional reverse remodeling in patients with New York Heart Association class I/II heart failure Circulation 120 19 2009 1858 1865
26. A.J. Moss, W.J. Hall, D.S. Cannom, and et al. Cardiac-resynchronization therapy for the prevention of heart-failure events N Engl J Med 361 14 2009 1329 1338
27. S.D. Solomon, E. Foster, M. Bourgoun, and et al. Effect of cardiac resynchronization therapy on reverse remodeling and relation to outcome: multicenter automatic defibrillator implantation trial: cardiac resynchronization therapy Circulation 122 10 2010 985 992
28. W. Zareba, H. Klein, I. Cygankiewicz, and et al. Effectiveness of cardiac resynchronization therapy by QRS morphology in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT) Circulation 123 10 2011 1061 1072
29. M. Bohm, K. Swedberg, M. Komajda, and et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial Lancet 376 9744 2010 886 894
30. K. Swedberg, M. Komajda, M. Bohm, and et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study Lancet 376 9744 2010 875 885
31. J.P. Koepke, and G.F. DiBona Functions of the renal nerves Physiologist 28 1 1985 47 52
32. J.B. Oldham Denervation of the kidney Ann R Coll Surg Engl 7 3 1950 222 245
33. M. Epstein, and E. de Marchena Is the failure of SYMPLICITY HTN-3 trial to meet its efficacy endpoint the "end of the road" for renal denervation? J Am Soc Hypertens 9 2 2015 140 149
34. K.A. Evelyn, M.M. Singh, W.P. Chapman, G.A. Perera, and H. Thaler Effect of thoracolumbar sympathectomy on the clinical course of primary (essential) hypertension. A ten-year study of 100 sympathectomized patients compared with individually matched, symptomatically treated control subjects Am J Med 28 1960 188 221
35. R.H. Smithwick, and J.E. Thompson Splanchnicectomy for essential hypertension; results in 1,266 cases JAMA 152 16 1953 1501 1504
36. J.E. Thompson, and R.H. Smithwick Surgical measures in hypertension Geriatrics 8 11 1953 611 619
37. H. Krum, M. Schlaich, R. Whitbourn, and et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study Lancet 373 9671 2009 1275 1281
38. Symplicity HTN-2 Investigators, Esler MD, Krum H, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the symplicity HTN-2 trial): a randomised controlled trial Lancet 376 9756 2010 1903 1909
39. D.L. Bhatt, D.E. Kandzari, W.W. O'Neill, and et al. A controlled trial of renal denervation for resistant hypertension N Engl J Med 370 15 2014 1393 1401
40. S. Ragot, N. Genes, L. Vaur, and D. Herpin Comparison of three blood pressure measurement methods for the evaluation of two antihypertensive drugs: feasibility, agreement, and reproducibility of blood pressure response Am J Hypertens 13 6 Pt 1 2000 632 639
41. M. Bohm, F. Mahfoud, C. Ukena, and et al. First report of the global SYMPLICITY registry on the effect of renal artery denervation in patients with uncontrolled hypertension Hypertension 65 4 2015 766 774
42. G.L. Bakris, R.R. Townsend, J.M. Flack, and et al. 12-Month blood pressure results of catheter-based renal artery denervation for resistant hypertension: The SYMPLICITY HTN-3 trial J Am Coll Cardiol 65 13 2015 1314 1321
43. M.C. Brandt, F. Mahfoud, S. Reda, and et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension J Am Coll Cardiol 59 10 2012 901 909
44. S.H. Schirmer, M.M. Sayed, J.C. Reil, and et al. Improvements in left ventricular hypertrophy and diastolic function following renal denervation: effects beyond blood pressure and heart rate reduction J Am Coll Cardiol 63 18 2014 1916 1923
45. A.J. McLellan, M.P. Schlaich, A.J. Taylor, and et al. Reverse cardiac remodeling after renal denervation: atrial electrophysiologic and structural changes associated with blood pressure lowering Heart Rhythm 12 5 2015 982 990
46. E. Donal, L.H. Lund, E. Oger, and et al. Baseline characteristics of patients with heart failure and preserved ejection fraction included in the Karolinska Rennes (KaRen) study Arch Cardiovasc Dis 107 2 2014 112 121
47. W.L. Verloop, M.M. Beeftink, A. Nap, and et al. Renal denervation in heart failure with normal left ventricular ejection fraction. rationale and design of the DIASTOLE (DenervatIon of the renAl sympathetic nerves in hearT failure with nOrmal lv ejection fraction) trial Eur J Heart Fail 15 12 2013 1429 1437
48. Y. Yin Renal sympathetic modification in patients with heart failure ClinicalTrials.gov Identifier: NCT01402726 2011
49. S. Qijun Renal sympathetic denervation for patients with chronic heart failure (RSD4CHF) ClinicalTrials.gov Identifier: NCT01790906 2013
50. H. Krum Renal denervation in patients with chronic heart failure & renal impairment clinical trial (SymplicityHF) ClinicalTrials.gov Identifier: NCT01392196 2011
51. K. Sakakura, E. Ladich, Q. Cheng, and et al. Anatomic assessment of sympathetic peri-arterial renal nerves in man J Am Coll Cardiol 64 7 2014 635 643
52. A.R. Tzafriri, F. Mahfoud, J.H. Keating, and et al. Innervation patterns may limit response to endovascular renal denervation J Am Coll Cardiol 64 11 2014 1079 1087
53. M.P. Schlaich, E. Lambert, D.M. Kaye, and et al. Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and angiotensin neuromodulation Hypertension 43 2 2004 169 175
54. E.E. Vink, R. Goldschmeding, A. Vink, C. Weggemans, R.L. Bleijs, and P.J. Blankestijn Limited destruction of renal nerves after catheter-based renal denervation: results of a human case study Nephrol Dial Transplant 29 8 2014 1608 1610
55. Patrick Rossignol, Ziad A. Massy, Michel Azizi, George Bakris, Eberhard Ritz, Adrian Covic, and et al. For the ERA-EDTA EURECA-m working group, Red de Investigación Renal (REDINREN) network, and Cardiovascular and Renal Clinical Trialists (F-CRIN INI-CRCT) network. The double challenge of resistant hypertension and chronic kidney disease The Lancet 386 10003 2015 1588 1988
56. S. Desch, T. Okon, D. Heinemann, and et al. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension Hypertension 65 6 2015 1202 1208
57. J. Ceral, V. Habrdova, V. Vorisek, M. Bima, R. Pelouch, and M. Solar Difficult-to-control arterial hypertension or uncooperative patients? the assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy Hypertens Res 34 1 2011 87 90
58. M. Azizi, M. Sapoval, P. Gosse, and et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial Lancet 2015
59. J. Rosa, P. Widimsky, P. Tousek, and et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension: six-month results from the Prague-15 study Hypertension 65 2 2015 407 413
60. H.R. Warner The frequency-dependent nature of blood pressure regulation by the carotid sinus studied with an electric analog Circ Res 6 1 1958 35 40
61. A.M. Bilgutay, and C.W. Lillehei Treatment of hypertension with an implantable electronic device JAMA 191 1965 649 653
62. T.E. Lohmeier, E.D. Irwin, M.A. Rossing, D.J. Serdar, and R.S. Kieval Prolonged activation of the baroreflex produces sustained hypotension Hypertension 43 2 2004 306 311
63. D.A. Sica, and T.E. Lohmeier Baroreflex activation for the treatment of hypertension: principles and practice Expert Rev Med Devices 3 5 2006 595 601
64. S.I. Schwartz, L.S. Griffith, A. Neistadt, and N. Hagfors Chronic carotid sinus nerve stimulation in the treatment of essential hypertension Am J Surg 114 1 1967 5 15
65. A.N. Brest, L. Wiener, and B. Bachrach Bilateral carotid sinus nerve stimulation in the treatment of hypertension Am J Cardiol 29 6 1972 821 825
66. A.M. Bilgutay, and C.W. Lillehei Surgical treatment of hypertension with reference to baropacing Am J Cardiol 17 5 1966 663 667
67. T.E. Lohmeier, T.M. Dwyer, D.A. Hildebrandt, and et al. Influence of prolonged baroreflex activation on arterial pressure in angiotensin hypertension Hypertension 46 5 2005 1194 1200
68. J.H. Tordoir, I. Scheffers, J. Schmidli, and et al. An implantable carotid sinus baroreflex activating system: Surgical technique and short-term outcome from a multi-center feasibility trial for the treatment of resistant hypertension Eur J Vasc Endovasc Surg 33 4 2007 414 421
69. I.J. Scheffers, A.A. Kroon, J. Schmidli, and et al. Novel baroreflex activation therapy in resistant hypertension: results of a european multi-center feasibility study J Am Coll Cardiol 56 15 2010 1254 1258
70. J.D. Bisognano, G. Bakris, M.K. Nadim, and et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial J Am Coll Cardiol 58 7 2011 765 773
71. G.L. Bakris, M.K. Nadim, H. Haller, E.G. Lovett, J.E. Schafer, and J.D. Bisognano Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the rheos pivotal trial J Am Soc Hypertens 6 2 2012 152 158
72. J.D. Bisognano, C.L. Kaufman, D.S. Bach, E.G. Lovett, and P. de Leeuw DEBuT-HT and Rheos Feasibility Trial Investigators. Improved cardiac structure and function with chronic treatment using an implantable device in resistant hypertension: results from european and united states trials of the rheos system J Am Coll Cardiol 57 17 2011 1787 1788
73. M. Wallbach, L.Y. Lehnig, C. Schroer, and et al. Impact of baroreflex activation therapy on renal function - a pilot study Am J Nephrol 40 4 2014 371 380
74. U.C. Hoppe, M.C. Brandt, R. Wachter, and et al. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the barostim neo trial J Am Soc Hypertens 6 4 2012 270 276
75. M. Wallbach, L.Y. Lehnig, C. Schroer, and et al. Effects of baroreflex activation therapy on arterial stiffness and central hemodynamics in patients with resistant hypertension J Hypertens 33 1 2015 181 186
76. O. Borisenko, J. Beige, E.G. Lovett, U.C. Hoppe, and S. Bjessmo Cost-effectiveness of barostim therapy for the treatment of resistant hypertension in european settings J Hypertens 32 3 2014 681 692
77. Rossignol P. Economic evaluation of baroreceptor STIMulation for the treatment of resistant HyperTensioN (ESTIM-rHTN). ClinicalTrials.gov Identifier: NCT02364310, 2015.
78. K. Heusser, J. Tank, S. Engeli, and et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients Hypertension 55 3 2010 619 626
79. D. Robertson, A.S. Hollister, I. Biaggioni, J.L. Netterville, R. Mosqueda-Garcia, and R.M. Robertson The diagnosis and treatment of baroreflex failure N Engl J Med 329 20 1993 1449 1455
80. T.E. Lohmeier, D.A. Hildebrandt, T.M. Dwyer, and et al. Prolonged activation of the baroreflex decreases arterial pressure even during chronic adrenergic blockade Hypertension 53 5 2009 833 838
81. S. Burgoyne, D. Georgakopoulos, I. Belenkie, and J.V. Tyberg Systemic vascular effects of acute electrical baroreflex stimulation Am J Physiol Heart Circ Physiol 307 2 2014 H236 H241
82. D.L. Eckberg, M. Drabinsky, and E. Braunwald Defective cardiac parasympathetic control in patients with heart disease N Engl J Med 285 16 1971 877 883
83. M.T. La Rovere, G.D. Pinna, R. Maestri, and et al. Prognostic implications of baroreflex sensitivity in heart failure patients in the beta-blocking era J Am Coll Cardiol 53 2 2009 193 199
84. H.P. Brunner-La Rocca, M.D. Esler, G.L. Jennings, and D.M. Kaye Effect of cardiac sympathetic nervous activity on mode of death in congestive heart failure Eur Heart J 22 13 2001 1136 1143
85. J.N. Cohn, T.B. Levine, M.T. Olivari, and et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure N Engl J Med 311 13 1984 819 823
86. G. Grassi, G. Seravalle, B.M. Cattaneo, and et al. Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure Circulation 92 11 1995 3206 3211
87. G.J. Hasking, M.D. Esler, G.L. Jennings, D. Burton, J.A. Johns, and P.I. Korner Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity Circulation 73 4 1986 615 621
88. T.R. Porter, D.L. Eckberg, J.M. Fritsch, and et al. Autonomic pathophysiology in heart failure patients. Sympathetic-cholinergic interrelations J Clin Invest 85 5 1990 1362 1371
89. I.H. Zucker, J.F. Hackley, K.G. Cornish, and et al. Chronic baroreceptor activation enhances survival in dogs with pacing-induced heart failure Hypertension 50 5 2007 904 910
90. H.N. Sabbah, R.C. Gupta, M. Imai, and et al. Chronic electrical stimulation of the carotid sinus baroreflex improves left ventricular function and promotes reversal of ventricular remodeling in dogs with advanced heart failure Circ Heart Fail 4 1 2011 65 70
91. E. Gronda, G. Seravalle, G. Brambilla, and et al. Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: a proof-of-concept study Eur J Heart Fail 16 9 2014 977 983
92. W.T. Abraham, M.R. Zile, F.A. Weaver, and et al. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction JACC Heart Fail. 3 6 2015 487 496
93. K. Heusser, J. Tank, S. Engeli, and et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients Hypertension 55 3 2010 619 626
94. M. Doumas, D. Guo, and V. Papademetriou Carotid baroreceptor stimulation as a therapeutic target in hypertension and other cardiovascular conditions Expert Opin Ther Targets 13 4 2009 413 425
95. F.M. Abboud, and M.W. Chapleau Effects of pulse frequency on single-unit baroreceptor activity during sine-wave and natural pulses in dogs J Physiol 401 1988 295 308
96. A. Mortara, M.T. La Rovere, G.D. Pinna, and et al. Arterial baroreflex modulation of heart rate in chronic heart failure: clinical and hemodynamic correlates and prognostic implications Circulation 96 10 1997 3450 3458
97. M.T. La Rovere, J.T. Bigger Jr., F.I. Marcus, A. Mortara, and P.J. Schwartz Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (autonomic tone and reflexes after myocardial infarction) investigators Lancet 351 9101 1998 478 484
98. C. Zoccali, F. Mallamaci, S. Parlongo, and et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease Circulation 105 11 2002 1354 1359
99. M. Li, C. Zheng, T. Sato, T. Kawada, M. Sugimachi, and K. Sunagawa Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats Circulation 109 1 2004 120 124
100. J.J. Hamann, S.B. Ruble, C. Stolen, and et al. Vagus nerve stimulation improves left ventricular function in a canine model of chronic heart failure Eur J Heart Fail 15 12 2013 1319 1326
101. Y. Zhang, Z.B. Popovic, S. Bibevski, and et al. Chronic vagus nerve stimulation improves autonomic control and attenuates systemic inflammation and heart failure progression in a canine high-rate pacing model Circ Heart Fail 2 6 2009 692 699
102. H.N. Sabbah, I. Ilsar, A. Zaretsky, S. Rastogi, M. Wang, and Gupta RC Vagus nerve stimulation in experimental heart failure Heart Fail Rev 16 2 2011 171 178
103. P.J. Schwartz, G.M. De Ferrari, A. Sanzo, and et al. Long term vagal stimulation in patients with advanced heart failure: first experience in man Eur J Heart Fail 10 9 2008 884 891
104. T.A. Anholt, S. Ayal, and J.A. Goldberg Recruitment and blocking properties of the CardioFit stimulation lead J Neural Eng 8 3 2011 (034004-2560/8/3/034004. Epub 2011 May 5)
105. G.M. De Ferrari, H.J. Crijns, M. Borggrefe, and et al. Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure Eur Heart J 32 7 2011 847 855
106. L. Dicarlo, I. Libbus, B. Amurthur, B.H. Kenknight, and I.S. Anand Autonomic regulation therapy for the improvement of left ventricular function and heart failure symptoms: the ANTHEM-HF study J Card Fail 19 9 2013 655 660
107. R.K. Premchand, K. Sharma, S. Mittal, and et al. Autonomic regulation therapy via left or right cervical vagus nerve stimulation in patients with chronic heart failure: results of the ANTHEM-HF trial J Card Fail 20 11 2014 808 816
108. R.F. Redberg Sham controls in medical device trials N Engl J Med 371 10 2014 892 893
109. G.M. De Ferrari, A.E. Tuinenburg, S. Ruble, and et al. Rationale and study design of the NEuroCardiac TherApy foR heart failure study: NECTAR-HF Eur J Heart Fail 16 6 2014 692 699
110. F. Zannad, G.M. De Ferrari, A.E. Tuinenburg, and et al. Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the neural cardiac therapy for heart failure (NECTAR-HF) randomized controlled trial Eur Heart J 2014
111. P.J. Hauptman, P.J. Schwartz, M.R. Gold, and et al. Rationale and study design of the increase of vagal tone in heart failure study: INOVATE-HF. Am Heart J 163 6 2012 954 962.e1.
112. F. Zannad, W.G. Stough, F. Mahfoud, and et al. Design considerations for clinical trials of autonomic modulation therapies targeting hypertension and heart failure Hypertension 65 1 2015 5 15
113. D.P. Zipes, P. Neuzil, H. Theres, and et al. Determining the feasibility of spinal cord neuromodulation for the treatment of chronic systolic heart failure: the DEFEAT-HF study JACC Heart Fail 2015
114. G.M. De Ferrari, and P.J. Schwartz Vagus nerve stimulation: from pre-clinical to clinical application: challenges and future directions Heart Fail Rev 16 2 2011 195 203
115. B. Horn, J. Balk, and J.I. Gold Revisiting the sham: is it all smoke and mirrors? Evid Based Complement Alternat Med 2011 2011 842767